Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Prophylactic Therapy Response in Children with Abdominal Migraine: A Single Centre Experience in Oman

  • Received : 2021.07.04
  • Accepted : 2022.02.06
  • Published : 2022.03.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Abdominal migraine (AM) is a very common functional gastrointestinal disorder in children. This study reports the clinical features and response of AM to prophylactic treatment in children. Methods: This retrospective study was conducted between January 2010 and December 2019 at the Royal Hospital in the Sultanate of Oman. This study included children aged ≤ 13 years with a diagnosis of AM based on the Rome IV criteria for functional diagnoses. Clinical, demographic, and treatment data were collected. Results: Seventy-four children were identified, of which 43 were eligible for inclusion in this study. The median age at the onset of symptoms was 7 years (range, 2-12 years). The most frequent symptoms were headache (81.4%), nausea (79.1%), and vomiting (72.1%). Of the total cohort, 46.5%, 23.3%, and 6.9% received riboflavin, pizotifen, and propranolol monotherapy, respectively. Combination therapy was also used; 16.3% of children received pizotifen and propranolol, 4.7% received riboflavin and pizotifen, and 2.3% received riboflavin and propranolol. Patients treated with propranolol monotherapy showed 100% clinical improvement and those treated with riboflavin or pizotifen monotherapy showed 90% clinical improvement. Response to combination therapy with pizotifen and propranolol was 71.4%, and with riboflavin and pizotifen was 100%. In addition, treatment response was significantly associated with the presence of vomiting (p=0.039). Conclusion: We found a favorable response to various modalities and combination treatments with riboflavin, pizotifen, and propranolol in children with AM. In addition, the presence of vomiting may predict treatment response.

Keywords

References

  1. Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional disorders: children and adolescents. Gastroenterology 2016. doi: 10.1053/j.gastro.2016.02.015. [Epub ahead of print].
  2. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24 Suppl 1:9-160. https://doi.org/10.1111/j.1468-2982.2003.00824.x
  3. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629-808. https://doi.org/10.1177/0333102413485658
  4. Angus-Leppan H, Saatci D, Sutcliffe A, Guiloff RJ. Abdominal migraine. BMJ 2018;360:k179.
  5. Abu-Arafeh I, Russell G. Prevalence and clinical features of abdominal migraine compared with those of migraine headache. Arch Dis Child 1995;72:413-7. https://doi.org/10.1136/adc.72.5.413
  6. Carson L, Lewis D, Tsou M, McGuire E, Surran B, Miller C, et al. Abdominal migraine: an underdiagnosed cause of recurrent abdominal pain in children. Headache 2011;51:707-12. https://doi.org/10.1111/j.1526-4610.2011.01855.x
  7. Saps M, Velasco-Benitez CA, Langshaw AH, Ramirez-Hernandez CR. Prevalence of functional gastrointestinal disorders in children and adolescents: comparison between Rome III and Rome IV criteria. J Pediatr 2018;199:212-6. https://doi.org/10.1016/j.jpeds.2018.03.037
  8. Mortimer MJ, Good PA. The VER as a diagnostic marker for childhood abdominal migraine. Headache 1990;30:642-5. https://doi.org/10.1111/j.1526-4610.1990.hed3010642.x
  9. Saps M, Nichols-Vinueza DX, Rosen JM, Velasco-Benitez CA. Prevalence of functional gastrointestinal disorders in Colombian school children. J Pediatr 2014;164:542-5.e1. https://doi.org/10.1016/j.jpeds.2013.10.088
  10. Korterink J, Devanarayana NM, Rajindrajith S, Vlieger A, Benninga MA. Childhood functional abdominal pain: mechanisms and management. Nat Rev Gastroenterol Hepatol 2015;12:159-71. https://doi.org/10.1038/nrgastro.2015.21
  11. Mani J, Madani S. Pediatric abdominal migraine: current perspectives on a lesser known entity. Pediatric Health Med Ther 2018;9:47-58. https://doi.org/10.2147/PHMT.S127210
  12. Di Lorenzo C, Colletti RB, Lehmann HP, Boyle JT, Gerson WT, Hyams JS, et al. Chronic abdominal pain in children: a technical report of the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005;40:249-61. https://doi.org/10.1097/01.MPG.0000154661.39488.AC
  13. Cuvellier JC, Lepine A. Childhood periodic syndromes. Pediatr Neurol 2010;42:1-11. https://doi.org/10.1016/j.pediatrneurol.2009.07.001
  14. Condo M, Posar A, Arbizzani A, Parmeggiani A. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain 2009;10:361-5. https://doi.org/10.1007/s10194-009-0142-2
  15. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998;50:466-70. https://doi.org/10.1212/WNL.50.2.466
  16. Barbiroli B, Montagna P, Cortelli P, Funicello R, Iotti S, Monari L, et al. Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 1992;42:1209-14. https://doi.org/10.1212/WNL.42.6.1209
  17. Montagna P, Cortelli P, Monari L, Pierangeli G, Parchi P, Lodi R, et al. 31P-magnetic resonance spectroscopy in migraine without aura. Neurology 1994;44:666-9. https://doi.org/10.1212/WNL.44.4.666
  18. Symon DN, Russell G. Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine. Arch Dis Child 1995;72:48-50. https://doi.org/10.1136/adc.72.1.48
  19. Worawattanakul M, Rhoads JM, Lichtman SN, Ulshen MH. Abdominal migraine: prophylactic treatment and follow-up. J Pediatr Gastroenterol Nutr 1999;28:37-40. https://doi.org/10.1097/00005176-199901000-00010